司库奇尤单抗治疗银屑病关节炎2年结果:FUTURE 5研究
FUTURE 5研究2年结果显示,司库奇尤单抗300mg负荷、150mg负荷及150mg无负荷方案在活动性银屑病关节炎患者中持续改善临床终点,影像学进展低,无新安全性发现。996例随机患者中783例(78.6%)完成2年治疗。
要点
- 司库奇尤单抗300mg和150mg方案2年临床疗效持续。
- 2年无影像学进展比例:300mg组89.5%,150mg组82.3%,150mg无负荷组81.1%。
- 安全性分析与52周一致,无新发现。
核心结论
- 司库奇尤单抗含或不含负荷方案在银屑病关节炎患者中提供持续2年的临床疗效和低影像学进展。
研究设计与样本
- FUTURE 5研究为随机对照试验,活动性银屑病关节炎成人按2:2:2:3随机接受司库奇尤单抗300mg负荷、150mg负荷、150mg无负荷或安慰剂。
主要发现
- 996例随机患者中783例(78.6%)完成2年治疗,临床终点改善持续至2年。
- 2年vdH-mTSS平均变化(SD):300mg组0.10(1.74),150mg组0.52(2.66),150mg无负荷组0.41(2.20)。
- 2年无影像学进展(vdH-mTSS较基线变化≤0.5)比例:300mg组89.5%,150mg组82.3%,150mg无负荷组81.1%。
关键数值与推荐
- 无影像学进展定义为vdH-mTSS较基线变化≤0.5。
- 从第52周起,基于医生评估若观察到活动性疾病征象,司库奇尤单抗可从150mg升级至300mg。
临床怎么用
- 司库奇尤单抗300mg或150mg方案可用于活动性银屑病关节炎的持续治疗,2年影像学进展低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Secukinumab provided sustained efficacy, low radiographic progression and consistent safety over 52 weeks in patients with psoriatic arthritis (PsA) in the FUTURE 5 study. Here, we report 2-year (end-of-study) results from this study. METHODS: Adults with active PsA were randomised 2:2:2:3 to receive subcutaneous secukinumab 300 mg load (300 mg), 150 mg load (150 mg), 150 mg no load or placebo at baseline; weeks 1, 2, 3 and 4; and every 4 weeks thereafter. Secukinumab could be escalated from 150 mg to 300 mg starting at week 52, if active signs of disease were observed based on physician's assessment. Assessments at week 104 (2 years) included clinical end points and radiographic damage (mean change in van der Heijde-modified total Sharp score (vdH-mTSS)). Safety analysis included all patients who received ≥1 dose of study medication. RESULTS: Of the 996 patients randomised, 783 patients (78.6%) completed 2 years of treatment. Improvement in clinical end points was sustained through 2 years. The vdH-mTSS (mean change (SD)) was 0.10 (1.74; 300 mg), 0.52 (2.66; 150 mg) and 0.41 (2.20; 150 mg no load) at 2 years. The proportion of patients with no radiographic progression (change from baseline in vdH-mTSS ≤0.5) at 2 years was 89.5% (300 mg), 82.3% (150 mg) and 81.1% (150 mg no load). CONCLUSION: Secukinumab with and without loading regimen provided sustained clinical efficacy and low radiographic progression through 2 years in patients with PsA. No new safety findings were reported. TRIAL REGISTRATION NUMBER: NCT02404350.
引用
- Mease PJ, Landewé R, Rahman P, et al. Secukinumab provides sustained improvement in signs and symptoms and low radiographic progression in patients with psoriatic arthritis: 2-year (end-of-study) results from the FUTURE 5 study. RMD Open. 2021. PMID: 34330846. doi:10.1136/rmdopen-2021-001600
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。